Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Lung Neoplasms

Anti-Inflammatory Agents

Antineoplastic Agents

Antiemetics

Gastrointestinal Agents

All Drugs and Chemicals

Analgesics

Central Nervous System Depressants

Dexamethasone

Dexmedetomidine

Ropivacaine

Dexamethasone acetate

Glucocorticoids

Hormones

Hormone Antagonists

Antineoplastic Agents, Hormonal

Hypnotics and Sedatives

Analgesics, Non-Narcotic

Adrenergic Agents

Adrenergic alpha-Agonists

Adrenergic Agonists

Neurotransmitter Agents

thoracic paravertebral blocks using a combination of ropivacaine and dexmedetomidine 100 ug every time

thoracic paravertebral blocks using a combination of ropivacaine and dexamethasone 10 mg every time

thoracic paravertebral blocks using only ropivacaine

combination of ropivacaine and dexmedetomidine 100 ug every time

Dexmedetomidine Group

combination of ropivacaine and dexamethasone 10mg every time

dexamethasone group

control group

This study was a prospective, randomized, controlled, and double-blind trial. Major assessments were made during the operation and 48 h postoperatively.

The prime outcomes were the time in minutes from leave the postoperative care unit to the first patient-controlled intravenous analgesia press.The secondary outcomes were to compare the following: (1)blood concentrations of ropivacaine was measured at 0.5 h, 1 h, 2 h, 3 h, and 24 h after paravertebral nerve block; and (2) the patient's intraoperative opioid use, phenylephrine use, fluid intake, urine output, dry mouth score, and 24 h and 48 h visual analogue scale.

thoracic paravertebral blocks using a combination of ropivacaine and dexmedetomidine or dexamethasone

Comparison of the Duration of Ropivacaine Combined With Dexmedetomidine or Dexamethasone on Paravertebral Block

Comparison of the Duration of Ropivacaine Combined With Dexmedetomidine or Dexamethasone on Paravertebral Block in Patients Undergoing Video-assisted Thoracic Surgery

The prime outcomes were the time in minutes from leave the postoperative care unit to the first patient-controlled intravenous analgesia press

(The secondary outcomes were to compare the following: (1)blood concentrations of ropivacaine was measured at 0.5 h, 1 h, 2 h, 3 h, and 24 h after paravertebral nerve block; and (2) the patient's intraoperative opioid use, phenylephrine use, fluid intake, urine output, dry mouth score, and 24 h and 48 h visual analogue scale.

China Medical University, China

Professor

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Uterine Neoplasms

Genital Neoplasms, Female

Urogenital Neoplasms

Uterine Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Anesthetics

dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to 24 h after surgery

Dexmedetomidine group

Control group

Surgical stress and anesthesia may cause immunosuppression in immunocompromised cancer patients. The natural killer (NK) cell is a critical part of anti-tumor immunity. Dexmedetomidine has sympatholytic effect and preserves NK cell function. This study investigate the effect of dexmedetomidine on immune suppression and postoperative outcomes in patients undergoing uterine cancer resection.

The Effects of Perioperative Dexmedetomidine Administration on Immune Suppression and Outcomes in Patients With Uterine Cancer Undergoing Radical Resection

Natural killer cell cytotoxicity is measured with NK Vue Kit™(ATGen, Gyeonggi-do, Korea).

inflammatory response is assessed by measuring levels of proinflammatory cytokines.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Comparison of the Duration of Ropivacaine Combined With Dexmedetomidine or Dexamethasone on Paravertebral Block	NCT03570645	Lung Cancer	Dexmedetomidine... dexamethasone g... control group	18 Years - 65 Years	China Medical University, China
The Effects of Perioperative Dexmedetomidine Administration on Immune Suppression and Outcomes in Patients With Uterine Cancer Undergoing Radical Resection	NCT02896413	Uterine Cancer	Dexmedetomidine... Control group	20 Years - 70 Years	Yonsei University

Spots Global Cancer Trial Database for dexmedetomidine group